This article reviews the challenges and progress of GBS vaccines, highlighting advances in clinical development.
The global burden of Group B streptococcal (GBS) disease remains high and an effective vaccine in pregnancy is an unmet public health need. GBS vaccines have been in development for decades, with earlier work providing evidence of immunogenicity and safety but not resulting in a licensed product. More recently, two vaccine candidates have reached advanced stages of clinical development. This article reviews the progress towards a GBS vaccine, the challenges that lie ahead and how they might be overcome.
No takes yet. Share an insight, caveat, or question.
Thorn et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: